Abstract 634P
Background
Long course chemoradiotherapy (LCCRT) for locally advanced rectal cancer (LARC) results in a complete pathological CR in 10-30% of patients (pts). Radiotherapy (RT) is immuno-stimulatory by enhancing tumour cell death, but also immunosuppressive stimulating PDL1 production and myeloid-derived suppressor cells. PDL1 inhibition may be required to enhance RT immuno-stimulatory effects. Hypothesis: In pts with resectable LARC, Avelumab given post LCCRT may enhance tumour response rates whilst reducing relapses.
Methods
Phase II single arm trial. Pts had LCCRT (50.4Gy + 5FU [225mg/m2/day/CI] or Capecitabine [825mg/m2 BID]/5.5 weeks). Post LCCRT pts received 4 cycles Avelumab (AV) (10mg/kg, q2 weeks), then resection 10-12 weeks post LCCRT. Fresh tumour biopsy/ctDNA sampling taken at pre LCCRT, pre AV and at surgery. Response by FDG PET and pelvic MRI. Inclusion Criteria: pts with MRI stage T3b-4/N1-2/M0 LARC , tumoural lower border <12cm from anal verge, measurable disease, ECOG 0-1, adequate organ function. Endpoints: (a) Primary; Complete pathological response rate (Target ≥ 35%) reported centrally, (b) Secondary; Imaging responses, Toxicity. (c) Exploratory; Tumoural immune cell subsets/checkpoint expression and ctDNA analysis, Distant relapse-free survival and the sites of relapse.
Results
37 pts entered. Baseline TNM: T3b-d 75%, T4a-b 25%. 33 pts completed LCCRT, 31 pts (83%) had all 4 cycles of AV and 32 pts (86%) had surgery. ORR Pelvic MRI (N=33): 2 CR, 14 PR, 31 DCR. FDG PET: 10 CMR, 18 PMR.. 10 pts Grade 3 AEs, 3 pts with treatment-related G3 and no G4 AEs. No immune-related G3 AEs. Post-operative complications as expected. Pathological response (Modified Ryan Score) (N=32): Complete pathCR (18.7%), near CR (15.7%), in MSI-H (N=4), 50% and 25% resp. Median followup 3.1 yrs: 3 yr est. time to progression 82%, distant relapse free survival 80%, disease free survival 80%.
Conclusions
The Ave-Rec phase II study has shown Avelumab post LCCRT is safe with significant imaging responses and complete/near-complete path response rate of 34.3% in pts with ESMO high risk rectal cancers. Parallel translational studies are ongoing. The addition of immune checkpoint inhibitors warrants further evaluation in LARC.
Clinical trial identification
NCT03299660.
Editorial acknowledgement
Legal entity responsible for the study
M. Michael.
Funding
Merck Pty Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
649P - The genomic landscape of appendiceal adenocarcinoma (AA) revealed by 855 whole exome sequences (WES)
Presenter: Michael White
Session: Poster session 11
650P - Genomic profiling of small bowel adenocarcinoma: A pooled analysis
Presenter: Thomas Aparicio
Session: Poster session 11
651P - DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study
Presenter: Christophe Borg
Session: Poster session 11
726P - Circulating cell-free DNA-based biomarkers as a new tool for prognosis and surveillance of adrenocortical carcinoma
Presenter: Cristina Ronchi
Session: Poster session 11
727P - Clinical outcome of anlotinib (A) and tislelizumab (T) in metastatic adrenocortical carcinoma(mACC): A one-arm single-center experience
Presenter: HAO LI
Session: Poster session 11
728P - Brain metastases in advanced thyroid carcinoma: Clinical and molecular characteristics and outcomes
Presenter: Thais Megid
Session: Poster session 11
729P - Prognostic significance of nodal micrometastases in patients with non-functioning pancreatic neuroendocrine tumors (NF-PanNETs): A survival analysis from a prospective observational study
Presenter: Valentina Andreasi
Session: Poster session 11
730P - The outcome of combine radioligand and CAPTEM therapy in patients with advanced, unresectable, progressive GEP-NET
Presenter: Jaroslaw Cwikla
Session: Poster session 11
748P - Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
Presenter: Emeline Colombo
Session: Poster session 11